National pharmacare in Canada: Open consultation until September 28

Health Canada is requesting public input by September 28, 2018 on how to implement affordable national pharmacare for Canadians and their families.

While Canadians benefit from a publicly funded health care system, prescription drugs are not covered in a consistent way across the country. Key considerations with this consultation include who would receive pharmacare, which types of drugs are covered, and how it is financed.

We are in favour of a national pharmacare program to ensure Canadian families have access to affordable medications, including epinephrine auto-injectors, the first-line treatment for anaphylactic reactions.

Help us advocate for accessible epinephrine auto-injectors. 

Here’s what you can do:

  • Get informed: Click here for details on the consultation request from the Council and read their Discussion Paper which outlines the key issues. You can also read our submission to the Council, where we encourage measures to provide accessible and affordable medication to Canadian families, including epinephrine auto-injectors, life-saving devices used to treat serious allergic reactions.
  • Provide your feedback: Let Health Canada know that Canadian families should have a national pharmacare program that provides access to affordable life-saving epinephrine auto-injectors. Be sure to email the Council at pharmacare-assurancemedicaments@canada.ca by September 28, 2018, which is the deadline for feedback. You can also to share your thoughts by participating in the online discussion forum and by completing the online questionnaire.
  • Share, share, and share: Share this with others and encourage as many people as possible to contact the Council to make our collective voice heard.

We will continue to advocate on your behalf to ensure that all Canadians have access to epinephrine.